Is Ripretinib included in medical insurance?

Ripretinib is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumors (GIST) who have been previously treated with three or more kinase inhibitors, including imatinib. Gastrointestinal stromal tumors, the most common type of gastrointestinal sarcoma, are cancers that affect structures in the digestive tract or near the abdomen, often in the stomach or small intestine.

Most gastrointestinal stromal tumors are caused by a series of mutations, with the most common primary mutations occurring in the KIT kinase, accounting for approximately 80% of cases, or the PDGFRA kinase, accounting for approximately 5%-10% of cases. Current therapies are unable to suppress the full spectrum of primary and secondary mutations that contribute to drug resistance and disease progression. In the pivotal INVICTUS phase trial, patients with advanced gastrointestinal stromal tumor who had progressed on at least one of imatinib, sunitinib, and regorafenib who received repetinib had significantly longer progression-free survival (the primary endpoint) and overall survival than patients who received placebo.

The original drug of Ripetinib has been marketed in China and has been approved by the National Medical Insurance Bureau to enter the scope of Class B medical insurance, but it is limited to patients who meet the indications. The price of each box of 50mg*30 tablets may be around 30,000 yuan. The expensive price may increase the pressure on families with heavy financial burdens. The US version of Ripetinib Specifications50mg*90 tablets sold overseas may be priced around RMB 77,000 per box (the price may fluctuate due to exchange rates). The ingredients of foreign original drugs are basically the same as those of domestic original drugs. Currently, there is no generic drug of Ripetinib produced and marketed overseas. For specific prices and drug information, please consult Yaode’s medical consultant.